The EU’s HTA regulation: Are we ready for kick-off?

On Tuesday, 8 October 2024 ECO Community 365 Roundtable series put a spotlight on the issue of ‘EU HTA Cooperation’

A landmark piece of European Union legislation to achieve greater cooperation between countries on Health Technology Assessment (HTA) is due to come into force in January 2025, with cancer medicines among the first group of therapies in its focus. Is the EU ready for Joint Clinical Assessments? Have stakeholder views been taken account of? Is there still time to address any remaining concerns?

The Roundtable was co-chaired by Natacha Bolaños, Regional Manager for Europe at the Lymphoma Coalition, and Eric Van Cutsem, Board Member of the European Cancer Organisation and Head of Digestive Oncology at the University Hospitals Gasthuisberg & KULeuven.

08 October 2024 15:00 - 17:30 CEST

Virtual

community 365 roundtable eu hta cooperation visual 1

Programme

15:00-15:20 Welcome and introductions  

Introduction to the HTA regulation and progress so far. Introductory remarks by:

  • Natacha Bolaños, Regional Manager for Europe, Lymphoma Coalition
  • Eric Van Cutsem, Board Member, European Cancer Organisation, Head of Digestive Oncology, University Hospitals Gasthuisberg & KULeuven
15:20-16:00 Session 1: EU level HTA decisions – Who decides and how? 

Session co-chaired by Eric Van Cutsem, Board Member, European Cancer Organisation, Head of Digestive Oncology, University Hospitals Gasthuisberg & KULeuven and Hilary Hansen, Global Public Affairs Lead, Oncology, Sanofi.

Presentation on governance and decision-making processes associated to the HTA Regulation, and the results of the Commission consultation on conflict of interest. 

  • Lise-lott Eriksson, President MPE, Myeloma Patient Europe
  • Marco Marchetti, Director, National Center for Health Technology Assessment, Istituto Superiore di Sanita 
  • Béla Dajka, Health Policy Officer, DG Sante European Commission
  • Robin Doeswijk, Head of European Affairs, European Hematology Association
16:00-16:40 Session 2: How will data be used to support EU level Joint Clinical Assessments?

Session co-chaired by Natacha Bolaños, Regional Manager for Europe, Lymphoma Coalition and Kostas Papadakis, Head of Oncology Market Access, Bayer

Expert discussion with audience and: 

  • Ansgar Hebborn, Roche Pharma's Head of Global HTA & Payment Policy
  • Panos Kanavos, Deputy Director at LSE Health, London School of Economics
  • Tamara Hussong Milagre, President at EVITA, ePAG Representative at European Reference Network GENTURIS, EUPATI fellow
16:40-17:20 Session 3: Are countries ready for implementing the EU HTA regulation? 

Co-chaired by Eric Van Cutsem and Sandro Cesaro, Head of Market Access and Innovative Value Strategies EUCAN, AstraZeneca

Expert discussion with audience and: 

  • Valentina Strammiello, Director of Strategic Initiatives, European Patients Forum
  • Mihai Rotaru, Director Market Access, EFPIA
17:20-17:30 Closing remarks and summary 

Contribution from Tomislav Sokol MEP

 

Speakers

  • Natacha Bolaños ECO Patient Advisory Committee Member, Regional Manager for Europe, Lymphoma Coalition
  • Eric Van Cutsem Board Member, European Cancer Organisation, Head of Digestive Oncology, University Hospitals Gasthuisberg & KULeuven
  • Sandro Cesaro Head of Market Access and Innovative Value Strategies EUCAN, AstraZeneca
  • Béla Dajka Health Policy Officer, DG Sante European Commission
  • Robin Doeswijk Head of European Affairs, European Hematology Association
  • Lise-Lott Eriksson President MPE, Myeloma Patient Europe
show all speakers (15)

Speakers

  • Natacha Bolaños ECO Patient Advisory Committee Member, Regional Manager for Europe, Lymphoma Coalition
  • Eric Van Cutsem Board Member, European Cancer Organisation, Head of Digestive Oncology, University Hospitals Gasthuisberg & KULeuven
  • Sandro Cesaro Head of Market Access and Innovative Value Strategies EUCAN, AstraZeneca
  • Béla Dajka Health Policy Officer, DG Sante European Commission
  • Robin Doeswijk Head of European Affairs, European Hematology Association
  • Lise-Lott Eriksson President MPE, Myeloma Patient Europe
show all speakers (15)
  • Natacha Bolaños ECO Patient Advisory Committee Member, Regional Manager for Europe, Lymphoma Coalition
  • Eric Van Cutsem Board Member, European Cancer Organisation, Head of Digestive Oncology, University Hospitals Gasthuisberg & KULeuven
  • Sandro Cesaro Head of Market Access and Innovative Value Strategies EUCAN, AstraZeneca
  • Béla Dajka Health Policy Officer, DG Sante European Commission
  • Robin Doeswijk Head of European Affairs, European Hematology Association
  • Lise-Lott Eriksson President MPE, Myeloma Patient Europe
  • Hilary Hansen Global Public Affairs Lead, Oncology, Sanofi
  • Ansgar Hebborn Head of Access Policy Affairs Europe and EFPIA HTA Working Group Chair
  • Tamara Hussong Milagre President at EVITA, ePAG Representative at European Reference Network GENTURIS, EUPATI fellow
  • Panos Kanavos Deputy Director, LSE Health, London School of Economics
  • Marco Marchetti Director, National Center for Health Technology Assessment, Istituto Superiore di Sanita
  • Kostas Papadakis Head of Oncology Market Access, Bayer
  • Mihai Rotaru Director Market Access, EFPIA
  • Tomislav Sokol MEP Member of the European Parliament
  • Valentina Strammiello Director of Strategic Initiatives, European Patients Forum

Speakers

  • Natacha Bolaños ECO Patient Advisory Committee Member, Regional Manager for Europe, Lymphoma Coalition
  • Eric Van Cutsem Board Member, European Cancer Organisation, Head of Digestive Oncology, University Hospitals Gasthuisberg & KULeuven
  • Sandro Cesaro Head of Market Access and Innovative Value Strategies EUCAN, AstraZeneca
  • Béla Dajka Health Policy Officer, DG Sante European Commission
  • Robin Doeswijk Head of European Affairs, European Hematology Association
  • Lise-Lott Eriksson President MPE, Myeloma Patient Europe
show all speakers (15)

Speakers

  • Natacha Bolaños ECO Patient Advisory Committee Member, Regional Manager for Europe, Lymphoma Coalition
  • Eric Van Cutsem Board Member, European Cancer Organisation, Head of Digestive Oncology, University Hospitals Gasthuisberg & KULeuven
  • Sandro Cesaro Head of Market Access and Innovative Value Strategies EUCAN, AstraZeneca
  • Béla Dajka Health Policy Officer, DG Sante European Commission
  • Robin Doeswijk Head of European Affairs, European Hematology Association
  • Lise-Lott Eriksson President MPE, Myeloma Patient Europe
show all speakers (15)